The adjusted odds ratio for Alzheimer disease among people diagnosed with ATTR-CM was 0.65, suggesting a lower likelihood of developing the disease compared with controls. Transthyretin-mediated ...

Two serious adverse events occurred, both of which resolved fully, and no deaths or life-threatening adverse events were reported. Prolonged treatment with tamoxifen was well tolerated in boys with ...

Key outcomes included high ILD prevalence, postmyopathic PPF in 13.5% of the cohort, higher rates of rapidly progressive ILD and transplantation in postmyopathic PPF, greater rituximab use in PPF, and ...

At 4 weeks post-surgery, the patient's anterior tibialis and quadriceps strength had improved from 2 to 3 out of 5 preoperatively to 4 out of 5. Routine fluoroscopy and high-magnification ...

Nasal involvement is the most commonly observed otolaryngologic feature in GPA, with symptoms often mimicking chronic rhinosinusitis. Destructive otolaryngologic manifestations in granulomatosis with ...

A qualitative matrix analysis allowed for the development of implementation strategies to improve the efficiency and effectiveness of the system. Researchers from the US identified an ideal system to ...

Rare Disease Advisor, a trusted source of medical news and feature content for healthcare providers, offers clinicians insight into the latest research to inform clinical practice and improve patient ...

Between 2001 to 2011, annual age-adjusted incidence increased from 0.55/100,000 to 0.78/100,000, demonstrating an increasing trend with age. Incidence peaks in individuals over 70 years of age ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired autoimmune neurological disorder in which both T-cell-mediated and humoral immune mechanisms target healthy myelinated ...

(L-R) Rare Disease Advisor senior correspondent Larry Luxner, patient columnists Alithea Athans, Tara Keith and Tom Bartlett, and director of advocacy relations Vera Luxner (Photo by Riya Ajmera) ...

Between 1970 and 1995, the incidence of new NHL cases increased. Between 2007 and 2016, new cases declined by approximately 0.9% per year, and mortality from NHL decreased by 2.2% per year. 3 ...

A new phase 2 clinical trial to test the safety, efficacy, and tolerability of TAK-411 for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) is now open. The open-label, ...